Facility
Novo Nordisk - Kalundborg, Denmark (API)
Operated by Novo Nordisk →DK
Primary injectable semaglutide API production (all Ozempic/Wegovy injectable API); worlds largest insulin production site also; $6.1B expansion investment 2024; sole source for injectable semaglutide API globally
0
Inputs produced
0
Goods downstream
0
Incidents on record
0
Stories